Cargando…

PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer

Derangement of the phosphatidylinositol-3 kinase (PI3K) pathway is implicated in several subtypes of breast cancers. Mutation or upregulation of PI3K enhances cancer cells’ survival, proliferation, and ability to metastasize, making it an attractive molecular target for systemic therapy. PI3K has fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhakal, Ajay, Acharya, Luna, O’Regan, Ruth, Gandhi, Shipra, Falkson, Carla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584833/ https://www.ncbi.nlm.nih.gov/pubmed/34769309 http://dx.doi.org/10.3390/ijms222111878

Ejemplares similares

Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor–Positive Breast Cancer
por: Sarma, Maithreyi, et al.
Publicado: (2020)

Neratinib-Induced Duodenal Ulcer: A Case Report
por: Moftakhar, Bahar, et al.
Publicado: (2020)

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
por: Paplomata, Elisavet, et al.
Publicado: (2013)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells
por: Ozbay, Tuba, et al.
Publicado: (2009)

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience
por: Alaklabi, Sabah, et al.
Publicado: (2022)

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
por: Mitri, Zahi, et al.
Publicado: (2012)

Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor–positive Breast Cancer
por: Jones, Robert B., et al.
Publicado: (2022)

AR Signaling in Breast Cancer
por: Rahim, Bilal, et al.
Publicado: (2017)

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
por: Dhakal, Ajay, et al.
Publicado: (2020)

Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?
por: Gupta, Ravi Kumar, et al.
Publicado: (2022)

Identification of Epidermal Growth Factor Receptor Tyrosine-Kinase Mutations in Non-small Cell Lung Cancer: Testing Platform Matters
por: Gandhi, Shipra, et al.
Publicado: (2020)

The Immunology of Hormone Receptor Positive Breast Cancer
por: Goldberg, Jonathan, et al.
Publicado: (2021)

MON-537 Fusion of Parathyroid Hormone to Growth Hormone Binding Protein Delays Clearance Whilst Retaining Biological Activity
por: Wilkinson, Ian, et al.
Publicado: (2019)

Mitotic regulation by NIMA-related kinases
por: O'Regan, Laura, et al.
Publicado: (2007)

Precision Medicine in Hormone Receptor-Positive Breast Cancer
por: Nasrazadani, Azadeh, et al.
Publicado: (2018)

Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment
por: Dobovišek, Luka, et al.
Publicado: (2020)

Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer
por: Gandhi, Shipra
Publicado: (2023)

Efficacy of chemotherapy after hormone therapy for hormone receptor–positive metastatic breast cancer
por: Mori, Ryutaro, et al.
Publicado: (2014)

PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come
por: De Mattos-Arruda, Leticia
Publicado: (2020)

The Effect of Young Age in Hormone Receptor Positive Breast Cancer
por: Lee, Minna K., et al.
Publicado: (2015)

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017)

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
por: Torres-Guzmán, Raquel, et al.
Publicado: (2017)

Combination Therapies in Advanced, Hormone Receptor–Positive Breast Cancer
por: Olson, Emily
Publicado: (2018)

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
por: Buqué, Aitziber, et al.
Publicado: (2020)

Weight Gain after Hormone Receptor-Positive Breast Cancer
por: Goyal, Archita, et al.
Publicado: (2022)

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
por: Matutino, Adriana, et al.
Publicado: (2018)

Targeting PI3KCA pathway to improve patient outcomes in hormone receptor-positive breast cancer: a worthy 20-year wager?
por: Saura, C
Publicado: (2019)

Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin
por: Rowe, Danica L., et al.
Publicado: (2009)

Considerations for payers in managing hormone receptor-positive advanced breast cancer
por: Chitre, Mona, et al.
Publicado: (2014)

Treating Elderly Patients With Hormone Receptor–Positive Advanced Breast Cancer
por: Riseberg, David
Publicado: (2015)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
por: D’Souza, Anishka, et al.
Publicado: (2018)

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer
por: Freelander, Allegra, et al.
Publicado: (2021)

Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer
por: Sebastian, William, et al.
Publicado: (2023)

Positive solutions of differential, difference and integral equations
por: Agarwal, Ravi P, et al.
Publicado: (1999)

Receipt of Standard Breast Cancer Treatment by African American and White Women
por: Worthington, Julie, et al.
Publicado: (2008)

Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study
por: Ritte, Rebecca, et al.
Publicado: (2013)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
por: Maselli, Angela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sme2pn1rvj1f6cm6plkvs940c0